Jüergen Wolf, MD, medical director of the Center for Integrated Oncology and professor of Interdisciplinary Translational Oncology at University Hospital of Cologne, discusses data the phase 2 GEOMETRY mono-1 trial with capmatinib (Tabrecta) in patients with METex14-mutated or high MET amplified advanced non–small cell lung cancer. Website: https://www.onclive.com Twitter: / onclive Facebook: / onclive LinkedIn: / onclive